ATXS

Astria Therapeutics, Inc. (ATXS) | Rumor.io

Astria Therapeutics

ATXS

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about ATXS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Oct 15

Astria Therapeutics, Inc. (ATXS) has been upgraded by analysts, with Wedbush downgrading its rating to Neutral from a previous $28 target to $13.
The company's stock price surged 37% on a $700M buyout deal with BioCryst, with analysts staying bullish on the long-term potential of the deal.
JMP Securities has updated its rating for Astria Therapeutics (ATXS) to Market Perform, with the company's acquisition by BioCryst seen as a strategic move to strengthen its HAE treatment pipeline.

Generated by AI

Sentiment

Of the messages about ATXS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	97.12% +31.04
Bearish	—	—	—	2.88% -31.04

Bullish· Oct 14

$ATXS has been gaining 74% in value since being held, indicating a strong uptrend.
The acquisition of $ATXS by $BCRX in a $700 million deal could be a good deal for both companies, potentially leading to further growth.
$ATXS has seen a significant price spike, with a breakout move and massive volume, suggesting momentum is driving the stock's performance.

Bearish· Jun 15

$ATXS is experiencing a pump and dump scenario, with true believers dumping their shares incrementally.
The stock has been shorted heavily, with many expecting a price drop to around $2.24.
There are concerns about the lack of shares available to short, with prices potentially increasing as a result.

Generated by AI

Topics

Of the messages about ATXS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	20.06%
Announcements	—	—	—	55.77%
Controversies	—	—	—	1.74%
Earnings	—	—	—	0.32%
Macro	—	—	—	17.22%
Technical Analysis	—	—	—	4.9%

Announcements· Oct 14

BioCryst Pharmaceuticals is acquiring Astria Therapeutics in a $700M deal, with Astria shareholders receiving $8.55 in cash and 0.59 shares of BioCryst common stock per share.
The acquisition implies a per-share value of $13, a premium of about 54% over Astria's last close, and has triggered a 35.1% surge in Astria's shares.
The deal is expected to strengthen BioCryst's rare diseases portfolio and add a promising hereditary angioedema drug to its treatment options.

Technical Analysis· Jan 29

$ATXS may see a take off if it holds above 4.80 until 3:30.
A fresh golden cross on the 4hr chart suggests higher numbers for $ATXS, with a possible gap-up on Monday.
Failing to break the triangle may result in $ATXS moving sideways, with a next possible target at the 200 EMA.

Generated by AI

Community

Of the messages about ATXS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	22.9%
Newcomers	—	—	—	77.1%

Also Discussed

Investors talking about ATXS also mention

#	Name	Attention
1	ALPN - Alpine Immune Sciences, Inc.	——
2	Daré Bioscience, Inc.DARE	0%0
3	Gyre Therapeutics Inc.GYRE	0%0
4	BLPH - Bellerophon Therapeutics, Inc.	——
5	YMAB - Y-mAbs Therapeutics, Inc.	——
6	Pulmatrix Inc.PULM	0%0
7	Adaptive Biotechnologies Corporation Common StockADPT	0%new
8	XMax Inc.NVFY	0%0
9	BIOS - BioPlus Acquisition Corp.	——
10	Xtant Medical Holdings Inc.XTNT	0%0